Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives $6.92 Average Target Price from Brokerages

Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Free Report) have received an average recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The […]

Leave a Reply

Your email address will not be published.

Previous post Killam Apartment REIT (TSE:KMP.UN) Receives C$22.23 Average Price Target from Brokerages
Next post Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Upgraded by Leerink Partnrs